E-LIB Suche - Ergebnisse für: Vilacha, Juliana F.

1

Structural Aspects of the ROS1 Kinase Domain and Oncogenic ..:

Vilachã, Juliana F. ; Wassenaar, Tsjerk A. ; Marrink, Siewert J.
Crystals. 14 (2024) 2 - p. 106 , 2024

Link: https://doi.org/10.3390/..

2

Feasibility of Follow-Up Studies and Reclassification in Sp..:

Ghorbani, Fatemeh ; Alimohamed, Mohamed Z. ; Vilacha, Juliana F....
Frontiers in Genetics. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

3

Actionability of on-target ALK Resistance Mutations in Pati..:

Koopman, Bart ; Groen, Harry J.M. ; Schuuring, Ed...
Clinical Lung Cancer. 23 (2022) 2 - p. e104-e115 , 2022

Link: https://doi.org/10.1016/..

4

New directions in antimalarial target validation:

Batista, Fernando A. ; Gyau, Benjamin ; Vilacha, Juliana F....
Expert Opinion on Drug Discovery. 15 (2020) 2 - p. 189-202 , 2020

Link: https://doi.org/10.1080/..

5

Making NSCLC Crystal Clear: How Kinase Structures Revolutio..:

Vilachã, Juliana F. ; Mitchel, Sarah C. ; Akele, Muluembet Z...
Crystals. 10 (2020) 9 - p. 725 , 2020

Link: https://doi.org/10.3390/..

6

Feasibility of Follow-Up Studies and Reclassification in Sp..:

Ghorbani, Fatemeh ; Alimohamed, Mohamed Z ; Vilacha, Juliana F...
https://research.rug.nl/en/publications/5e479db6-66c1-4848-9520-12924c4a7d85. , 2022

Link: https://hdl.handle.net/1..

7

Making NSCLC Crystal Clear:How Kinase Structures Revolution..:

Vilacha, Juliana F ; Mitchel, Sarah C ; Akele, Muluembet Z..
https://research.rug.nl/en/publications/f306cb6c-3e7d-4e83-9c1e-4c6516469b0e. , 2020

Link: https://hdl.handle.net/1..

8

New directions in antimalarial target validation:

Batista, Fernando A ; Gyau, Benjamin ; Vilacha, Juliana F...
https://research.rug.nl/en/publications/af981d6a-2596-4373-82f2-ea974e442613. , 2020

Link: https://hdl.handle.net/1..

9

Relevance and Effectiveness of Molecular Tumor Board Recomm..:

Koopman, Bart ; van der Wekken, A. J ; Elst, ter, Arja...
https://research.rug.nl/en/publications/ed859e22-18f5-4605-b768-72491951d0b9. , 2020

Link: https://hdl.handle.net/1..

10

Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P7..:

van Kempen, Léon C ; Wang, Hangjun ; Aguirre, Maria Leonor...
https://research.rug.nl/en/publications/0638aa33-b70f-419d-a9fa-b3914698e897. , 2018

Link: https://hdl.handle.net/1..

11

Feasibility of Follow-Up Studies and Reclassification in Sp..:

Fatemeh Ghorbani ; Mohamed Z. Alimohamed ; Juliana F. Vilacha...
https://www.frontiersin.org/articles/10.3389/fgene.2022.782685/full. , 2022

Link: https://doi.org/10.3389/..

12

DataSheet1_Feasibility of Follow-Up Studies and Reclassific..:

Fatemeh Ghorbani ; Mohamed Z. Alimohamed ; Juliana F. Vilacha...
doi:10.3389/fgene.2022.782685.s001. , 2022

Link: https://doi.org/10.3389/..

13

Making NSCLC Crystal Clear: How Kinase Structures Revolutio..:

Juliana F. Vilachã ; Sarah C. Mitchel ; Muluembet Z. Akele..
https://dx.doi.org/10.3390/cryst10090725. , 2020

Link: https://doi.org/10.3390/..

14

Making NSCLC Crystal Clear: How Kinase Structures Revolutio..:

Juliana F. Vilachã ; Sarah C. Mitchel ; Muluembet Z. Akele..
https://www.mdpi.com/2073-4352/10/9/725. , 2020

Link: https://doi.org/10.3390/..

15

Actionability of on-target ALK Resistance Mutations in Pati..:

Koopman, Bart ; Groen, Harry J. M ; Schuuring, Ed...
https://research.rug.nl/en/publications/c3cffbcb-c8ea-437d-a50b-3ac0cc486768. , 2022

Link: https://hdl.handle.net/1..